EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 9 July 2020

The innovative pharmaceutical industry announces new AMR Action Fund

AMR Action Fund

On 9 July more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR.

The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections.

Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development Read more

H. V. Baumbach's opinion piece for Euractiv

COVID-19 has demonstrated in a quite dramatic way the huge impact of a global threat on public health and economy. While the COVID-19 crisis took us by surprise, our world faces a silent threat that is predictable and preventable, writes Hubertus Von Baumbach, CEO of Boehringer Ingelheim.

The rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR – is a looming global crisis we have known for quite some time.

Antibiotic resistance kills about 700,000 people globally every year. Superbugs that are resistant to antibiotics are on the rise, affecting every aspect of medicine today. We rely on the availability of effective antibiotics to be able to do everything from wisdom tooth extractions to cancer chemotherapy. Read more

Statements

EFPIA response to the consultation on the pharmaceutical strategy roadmap
03 July 2020

EFPIA and its members stand ready to work with all stakeholders to create medical innovation and facilitate sustainable... Read more

Blogs

09072020 Time to join forces: The industry in the lead of the fight against AMR (Guest blog)...
09 July 2020 - David Earnshaw

Together, we must work to translate the current crisis into concrete action that will deliver solutions to address AMR.... Read more

Faster and better decisions: accelerating the digital transformation in the time of COVID-19...
07 July 2020 - Chris Walker

As the healthcare system evolves, we believe that Europe will need to encourage health data sharing, whilst respecting... Read more

New approaches, new solutions to ensuring access to medicines
03 July 2020 - Nathalie Moll

Finding solutions to delays and barriers to patients getting access to new treatments Read more

Events

c4c Multi-Stakeholder Meeting on Child Psychiatry
10 September 2020 (Brussels, Belgium)

The first c4c Multi-Stakeholder Meeting on Child Psychiatry seeks to facilitate dialogue and provide an opportunity... Read more

NEW DATES - EU Health Summit 2020
26 October 2020 (Virtual event)

The EU Health Coalition is delighted to announce the second edition of the EU Health Summit. Read more

Our latest publications

Key Trade Data Points on the EU27 Pharmaceutical Supply Chain
09 July 2020 (Publications)

In 2019, 86.2% of EU27 imports of Human Medicinal Products came from Europe Read more

2020: The Pharmaceutical Industry in Figures
30 June 2020 (Publications)

Our annual statistics leaflet Read more

COVID-19: EFPIA and IFPMA PhRMA ethical guidance
09 July 2020 (Publications)

During the COVID-19 pandemic, EFPIA and its members remained fully committed to EFPIA Code requirements. Read more

What we are reading

Reviewing orphan drugs law: A tough equation
On 06 July 2020 (Euractiv)

The Orphan Regulation was introduced in 2000 and its main objective was to address the challenge of regulating medicines... Read more

Europe should fill the gap and exercise leadership in health research
On 09 July 2020 (EU Health Coalition)

It is time to coordinate health research efforts across Europe through the implementation of a European Health Research... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu